Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
You may also be interested in...
UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.
UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.
Humira Drives Abbott’s Second Quarter Performance
With new Crohn’s indication, Humira sales jump 50 percent as firm’s pharma sales grow 17 percent.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: